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Background: Detection of dengue virus (DENV) soluble/excreted (s/e) form of the nonstructural-1 (NS1)
glycoprotein in patient acute-phase sera is ideal for diagnosis. The commercially-available detection assays are,
however, too expensive for routine use and have low specificity, particularly for the s/e NS1 glycoprotein of DENV-2
and DENV-4, which are important causes of lethal human disease worldwide.
Methods: Mouse monoclonal antibodies (MAbs) were generated and screened against s/e NS1 glycoprotein
purified from each DENV serotype to obtain those that reacted equally with each serotype, but not with yellow
fever virus (YFV) s/e NS1 glycoprotein or human serum proteins. One MAb, MAb 2C4.6, was further tested against
these DENV glycoproteins in human sera using simple, peroxidase-labelled secondary antibody/substrate-developed
dot-blot assays.
Results: Optimal quenching of endogenous human serum peroxidases was attained using 3% H2O2 in H20 for 5
min. MAb 2C4.6 showed an acceptable detection sensitivity of < 32 ng/ml for the s/e NS1 glycoprotein of each
DENV serotype but did not cross-react with the YFV s/e NS1 glycoprotein or human serum proteins. By contrast, the
LX1 epitope-specific MAb, 3D1.4, showed similar detection sensitivity against only the DENV-1 NS1 glycoprotein,
consistent with results from commercial DENV s/e NS1 glycoprotein detection assays.
DENV s/e NS1 glycoproteins were stable in human sera after drying on the nitrocellulose membranes and storage
for one month at ambient temperature (28°C) before being processed. The total assay time was reduced to 3 h
without any loss of detection sensitivity. This dot-blot format was ideal for the circulating immune complex
disruption step, which is required for increased DENV s/e NS1 glycoprotein detection.
Conclusions: This is the first study to determine the detection sensitivity of MAbs against known concentrations of
s/e NS1 glycoprotein from each DENV serotype. The preparation of patient serum samples for dot-blot assays can
be performed by staff with a basic level of training and storage at low temperatures (e.g., -80°C) is not necessary.
These simple, inexpensive (US$ 0.05/sample), robust, sensitive and relatively rapid assays, using improved MAbs
such as MAb 2C4.6, should be ideal for the diagnosis of all DENV serotypes in DENV endemic regions.
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Dengue viruses (DENVs) are the most important vector-
borne human viruses in the world, causing an estimated
50–100 million infections in 100 countries and resulting
in a self-limiting febrile illness called dengue fever (DF),
which is sometimes associated with haemorrhage [1].
Approximately 500 000 cases result in the more severe,
life-threatening forms, due to plasma leakage, severe
haemorrhage, shock and organ failure called either se-
vere dengue disease (SDD) or dengue haemorrhagic
fever/dengue shock syndrome (DHF/DSS). Up to 12 500
people (2.5% of all DF cases) die from SDD (DHF/DSS)
annually [1]. Four DENV serotypes (DENV-1 to DENV-
4) have been identified, each of which may cause SDD
(DHF/DSS).
During DENV infections, high concentrations of the na-
tive homo-hexameric form of the nonstructural-1 (NS1)
glycoprotein are secreted from infected mammalian cells
along with infectious DENV virions [2]. Purified secreted/
extracellular (s/e) DENV-2 NS1 glycoprotein added to
normal human sera could be detected by an enzyme-
linked immunosorbent assay (ELISA) using a DENV NS1
glycoprotein complex-reactive monoclonal antibody,
(MAb) 3D1.4 [3-5], with a sensitivity of 15 ng/ml [6]; al-
though the DENV-2 NS1 glycoprotein-specific MAb,
1H7.4 [3], was slightly more sensitive (4 ng/ml) [6]. How-
ever, the ELISA using MAb 1H7.4 failed to detect the s/e
NS1 glycoprotein in acute-phase sera from patients with
primary DENV-2 infections collected in Thailand [6]. This
assay also only detected the s/e NS1 glycoprotein in less
than 50% (DF: 40% and DHF/DSS: 45%) of acute-phase
sera from patients with secondary DENV-2 infections, at
concentrations from 70 ng/ml up to 15,000 ng/ml [6].
Since these serum samples had undergone several freeze-
thaw cycles, the results demonstrated the lability of the
DENV s/e NS1 glycoprotein, probably through disruption
of the relevant LD2 epitope (amino acid 25–33), [4] or loss
of the LD2 epitope through cleavage of the NS1 glycopro-
tein at the conserved (amino acid 100–GKRS–103) dibasic
amino-terminal protease cleavage site [7]. However, a cap-
ture ELISA using mouse and rabbit polyclonal antibodies
(PAbs) detected the s/e NS1 glycoprotein in a moderate
proportion of acute-phase sera from patients with either
primary (77% (10/13): 40 to 2,000 ng/ml) or secondary
(88% (14/16): 10 to 2,000 ng/ml) DENV-1 infections in
French Guiana [8], identifying the s/e NS1 glycoprotein as
a suitable target for DENV diagnostics.
MAbs used in DENV NS1 glycoprotein detection assays
should react equally with the NS1 glycoproteins of each
DENV serotype. However, MAb 3D1.4 and other MAbs
(MAbs 1A12.3, 4H3.4 and 3A5.4) that bound the DENV
complex LX1 epitope (amino acid 112–KYSWKTWGKA–
121) on the DENV NS1 glycoproteins reacted unequally
with synthetic peptides containing the corresponding LX1epitope of each DENV serotype, as follows: DENV-1 >
DENV-3 > DENV-2 = DENV-4 [4].
Subsequently available commercial DENV s/e NS1
glycoprotein detection ELISAs used MAb 3D1.4 or other
likely LX1 epitope-specific MAbs (Pan-E, PanBio/Inver-
ness, Brisbane, Queensland, Australia; Platelia, Bio-Rad
Laboratories, Marnes La Coquette, France, or Standard
Diagnostics Inc., Kyonggi-do, South Korea). These assays
are too expensive ($US 5 to 10/sample) for routine screen-
ing of DENV-infected patients in poor, endemic areas, and
have low sensitivity for the s/e NS1 glycoprotein of one or
more DENV serotypes [9-11]. The Pan-E, Platelia and
Standard Diagnostics DENV s/e NS1 glycoprotein detec-
tion ELISAs show low to moderate overall sensitivities
with acute phase DENV serum samples (Standard Diag-
nostics: 55%; Platelia: 56.5% [11]; Pan-E: 56.3%; Platelia:
68.0% [10]; Pan-E: 64.9%; Platelia: 83.2% [9]). These assays
also showed the highest sensitivity for DENV-1 (Standard
Diagnostics: 70%; Platelia: 70% [11]; Pan-E: 79%; Platelia:
87% [10]; Pan-E 78.6%; Platelia: 93% [9]) and the lowest
sensitivity for either DENV-2 (Standard Diagnostics: 41%;
Platelia: 38% [11]; Pan-E: 62%; Platelia: 63% [10]; Pan-E:
76%; Platelia 82% [9]), or DENV-4 (Standard Diagnostics:
40%; Platelia 73% [11]; Pan-E: 52%; Platelia: 79% [10]; Pan-
E: 36%; Platelia: 71% [9]). These results accounted for a
large multi-country evaluation giving the lowest sensitiv-
ities of Pan-E and Platelia s/e NS1 detection ELISAs with
acute-phase sera from Nicaraguan patients (Pan-E: 30%;
Platelia: 37%), due to nearly all being infected with DENV-
2 (94%), and not with DENV-1 (6%) or DENV-3 (0%) [10].
Thus, in summary, the strength of these assay reactions
varied with DENV serotype, in the following order:
DENV-1 > DENV-3 > DENV-2 > DENV-4, similar to the
anti-LX1 epitope MAbs [4].
More recent commercial DENV NS1 glycoprotein detec-
tion assays had even lower sensitivities. This was demon-
strated in two well-conducted studies of NS1 antigen strip
assays, Pan-E (average sensitivity: 45% (range 30–59%),
PanBio (average sensitivity: 58.6%: range 48.2–68.4%),
and Bio-Rad (average sensitivity: 58.6%: range 48.2–
68.4%) and the Standard Diagnostics lateral flow s/e
NS1 detection assay (mean sensitivity: 48.5%: range
38.5–58.7%) [11,12].
Commercially-available DENV NS1 glycoprotein de-
tection/semi-quantification assays are too expensive for
routine use in nearly all DENV endemic regions of the
world, and all show significant differences in ability to
detect the s/e NS1 glycoprotein of each DENV serotype
[9-11,13-16]. Therefore there is an urgent need to de-
velop improved MAbs for use in inexpensive DENV s/e
NS1 glycoprotein detection assays.
We previously showed that the s/e NS1 glycoprotein
from all four DENV serotypes could be detected in
Indonesian patient sera using a simple dot-blot format,
Figure 1 MAb 2C4.6 reactions with the s/e NS1 glycoprotein of
each DENV serotype in Western blot assays. Preparative Western
blot strips containing approximately 35 ng bands of the secreted/
extracellular (s/e) NS1 glycoprotein of DENV-1 (strip 1), DENV-2 (strip 2),
DENV-3 (strip 3), DENV-4 (strip 4), 2-mercaptoethanol-reduced DENV-2
(strip 5), or purified YFV (strip 6), a crude lysate of DENV-2 infected Vero
(monkey kidney fibroblast) cells (strip 7), or a human serum sample
previously treated with 3% (vol/vol) H2O2/PBS for 60 min to quench
endogenous human serum peroxidases before addition of SDS-
stacking buffer and the purified DENV-2 s/e NS1 glycoprotein (strip 8).
The strips were taped together and simultaneously processed by
sequential reaction steps with MAb 2C4.6, peroxidase-labelled goat
anti-mouse IgG (H&L) and 4-chloro-1-naphthol/3,3’diaminobenzidine
(CND) substrate. Due to variations in the heights of the preparative
strips of each sample, the locations of the average molecular weight
(Mr) markers (20 to 200 kDa), and the approximate Mr ranges where
the dimeric and monomeric forms of DENV s/e NS1 glycoproteins,
are shown. The DENV s/e NS1 glycoproteins were almost
exclusively converted into their monomeric forms by heat
(100°C for 3 min) treatment.
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were used [17]. However, these assays used an electro-
chemiluminescence (ECL) substrate coupled with photo-
graphic film, which is too expensive for routine use in
DENV endemic areas. One advantage was that the gly-
coproteins were stable for month-long periods when
dot-blotted, blocked, and dried onto nitrocellulose mem-
branes before being developed [Falconar, unpublished].
It is also likely that improved immunoperoxidase detec-
tion sensitivity could be obtained in Western blot or
dot-blot assays by incorporating Ni2+ ions into the
3,3’diaminobenzidine substrate, as demonstrated in im-
munohistochemical studies [18].
In the present study, we aimed to determine: a)
whether we could generate mouse MAbs that could
more equally detect the s/e NS1 glycoprotein of each
serotype without cross-reacting with yellow fever virus
(YFV) s/e NS1 glycoprotein or human serum proteins;
b) the optimal parameters for quenching endogenous
human serum peroxidases in simple dot-blot assays
using one of these MAbs and standard 4-chloro-1-naphthol
and 3,3’-diaminobenzidine tetrahydrochloride (CND) sub-
strate precipitation; c) the detection sensitivities of such a
MAb against the purified s/e NS1 glycoprotein of each
DENV NS1 glycoprotein in these dot-blot assays; d)
whether such a MAb would show superior detection of
the s/e NS1 glycoprotein of each DENV serotype com-
pared with MAb 3D1.4, which bound the LX1 epitope; e)
whether the detection sensitivity could be increased by in-
corporating 1 mM Ni2+ ions into the CND substrate step;
f ) whether the DENV s/e NS1 glycoproteins in human
sera were stable when blotted onto the membranes,
blocked, dried and stored at either ambient temperature
(28°C) or at 4°C, -20°C or -80°C before being processed; g)
whether these assays could be performed within a moder-
ate time period (e.g. 3 hours); and h) the approximate cost
of these assays (US$/sample).
Results
Purification of s/e NS1 glycoproteins of each DENV
serotype and YFV
Large (250–500 μg) quantities of the soluble/extracellular
(s/e) NS1 glycoproteins were obtained from DENV-1
(S#14 strain), DENV-2 (S#42 strain), DENV-3 (S#25strain)
and DENV-4 (S#10 strain) serotypes isolated in our study
site [19,20] and from yellow fever virus (YFV) (17D-204
strain) by immunoaffinity purification from large infected
Vero cell cultures as described previously [7,21]. These
purified s/e NS1 glycoproteins were used for all mouse
immunisations and immunoassays.
Monoclonal antibodies (MAbs)
In this study, only low numbers of the MAb-producing
hybridomas (1.7%: 16/960) showed strong cross-reactionswith the s/e NS1 glycoprotein of multiple different
DENV serotypes. MAb 2C4.6 was identified as a suitable
candidate for further studies by its reactions in the
preparative Western blot strip assays (Figure 1). In this
study, supernatant from two 48-well plates containing
MAb 2C4.6 (1 ml volume diluted 1:2 in PBS/T/M)
reacted strongly with the bands containing 35 ng of the
purified s/e NS1 glycoprotein of each DENV serotype but
reacted very weakly with the DENV-2 NS1 glycoprotein
when it was reduced with 2-mercaptoethanol. It did not
cross-react with either the s/e NS1 glycoprotein of YFV,
human serum proteins, or other cellular or DENV-2 pro-
teins in a DENV-2-infected Vero cell lysate. The DENV
s/e NS1 glycoproteins were almost exclusively converted
into their monomeric forms after heat treatment. There-
fore, MAb 2C4.6, which is of the immunoglobulin G (IgG)
2b subclass, specifically bound to a conformationally-
dependent (2-mercaptoethanol reduction-sensitive) epi-
tope on the s/e NS1 glycoprotein of each DENV serotype.
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quenching for DENV-2 s/e NS1 glycoprotein detection by
MAb 2C4.6 in dot-blot assays
The ability of 3% H2O2 in either PBS, 40% MeOH/PBS
or H2O to reduce the background noise in the dot-blot
assays was assessed using three-fold serial dilutions of
DENV-2 s/e NS1 glycoprotein prepared in neat human
sera (Figure 2). The blots treated with 3% H2O2 in H2O
for 5 min gave slightly lower backgrounds than treat-
ment with 3% H2O2 in PBS for 30 min. By contrast, the
use of 3% H2O2 diluted in 40% MeOH/PBS for 15 or 30
min resulted in higher backgrounds, thereby reducing
the detection sensitivity. The apparent maximum opti-
mal detection sensitivity for the DENV-2 s/e NS1 glyco-
protein was approximately 30 ng/ml (0.3 ng/dot). The
dot-blot assays were therefore apparently more sensitive
than Western blot assays; in previous studies using other
anti-DENV NS1 glycoprotein-specific MAbs, the max-
imum sensitivity was obtained with a 10 ng band [7,21].Figure 2 Optimal quenching of endogenous human serum
peroxidases in the DENV s/e NS1 glycoprotein dot-blot
detection assay. Serial three-fold dilutions (90, 30 and 10 ng/ml) of
immunoaffinity-purified DENV-2 s/e NS1 glycoprotein, and buffer
without DENV-2 NS1 glycoprotein (0 ng/ml), prepared in undiluted
human sera were added at 10 μl volumes to four sets of paired
5-mm squares marked on nitrocellulose membranes. These
membranes were then dried and cut for reaction with each of the
different solutions trialled for quenching endogenous human serum
peroxidases (as shown), before being washed and blocked. These
membranes were then processed by sequential reaction steps with
MAb 2C4.6, peroxidase-labelled goat anti-mouse IgG (H&L) and 4-
chloro-1-naphthol/3,3’diaminobenzidine (CND) substrate. The results
were obtained from one of duplicate experiments performed that
gave similar results.Using the optimal 3% H2O2 in H2O for 5 min quenching
method, with two-fold serial dilutions, the maximum de-
tection sensitivity for the s/e DENV-2 NS1 glycoprotein
was < 32 ng/ml using MAb 2C4.6 (Figure 3). An attempt
to improve the sensitivity by the addition of 1 mM Ni2+
to the 4-chloro-1-naphthol/3, 3’diaminobenzidine sub-
strate mixture resulted in reduced DENV s/e NS1 glyco-
protein detection sensitivities due to precipitation of the
4-chloro-1-naphthol (data not shown).
Consistent with the inability of MAb 2C4.6 to react
with a 35 ng band of the yellow fever virus s/e NS1
glycoprotein in the Western blot assay (Figure 1), this
MAb also showed no detectable reaction with 5.12 ng
(512 ng/ml) concentration of this glycoprotein in these
dot-blot assays (Figure 3).
Comparison of the reaction of MAb 2C4.6 and 3D1.4
against the s/e NS1 glycoprotein of all four DENV
serotypes in dot-blot assays
The ability of MAb 3D1.4 to react with the s/e NS1
glycoprotein of each DENV serotype in the dot-blot as-
says was compared to that of MAb 2C4.6. MAb 3D1.4
bound more strongly to the corresponding LX1 epitope
synthetic peptide sequence of the DENV-1 NS1 glyco-
protein than the corresponding peptide sequences of the
other DENV serotype [4], and the DENV-1 NS1 glyco-
protein using the Pan-E ELISA on serum samples from
DENV-1 infected patients [9,10]. In this study, MAb
3D1.4 showed a similar detection sensitivity to MAbFigure 3 Maximum dot-blot detection sensitivity of MAb 2C4.6
against the DENV-2 s/e NS1 glycoprotein. Serial two-fold
dilutions (512 to 8 ng/ml) of immunoaffinity-purified DENV-2 s/e NS1
and YFV s/e NS1 (512 ng/ml) glycoproteins prepared in undiluted
human sera were added at 10 μl volumes to paired 5-mm squares
marked on a nitrocellulose membrane. After being dried and treated
with 3% H2O2/H2O for 5 min to quench the endogenous human
serum peroxidases, this membrane was washed and blocked. The
membrane was then processed by sequential reaction steps with
MAb 2C4.6, peroxidase-labelled goat anti-mouse IgG (H&L) and 4-
chloro-1-naphthol/3,3’diaminobenzidine (CND) substrate. The results
were obtained from one of duplicate experiments performed that
gave similar results.
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protein, but had lower detection sensitivities against the
s/e NS1 glycoprotein of DENV-3 (approximately 64 ng/
ml), DENV-4 (approximately 100 ng/ml), and DENV-2
(approximately 128 ng/ml) (Figure 4). Thus, MAb 2C4.6
showed superior detection sensitivity to the s/e NS1
glycoprotein of each DENV serotype than MAb 3D1.4 in
these assays.
MAbs 1G5.4-A1-C3 and 1B6.4d, of the IgG2b sub-
class, also generated against the DENV NS1 glycopro-
tein showed the same DENV-2 > DENV-4 > DENV-1 >
DENV-3 and DENV-2-specific reactions in these
dot-blot assays (data not shown) as were observed in
Western blot assays, respectively [3,21,22].
Reaction of MAb 2C4.6 with s/e NS1 glycoprotein of each
DENV serotype and their stability when dried on
nitrocellulose membranes and stored at different
temperatures
Serial two-fold dilutions (from 512 to 2 ng/ml) of the puri-
fied s/e NS1 glycoprotein of each DENV serotype wereFigure 4 Detection sensitivities of MAb 2C4.6 and MAb 3D1.4
against the s/e NS1 glycoprotein of each DENV serotype. Serial
two-fold dilutions from 512 to 2 ng/ml of immunoaffinity-purified
s/e NS1 glycoprotein of each DENV serotype (DENV-1 to DENV-4) or
buffer only (0), prepared in undiluted human sera were added at 10
μl volumes to duplicate paired 5-mm squares marked on a
nitrocellulose membrane. After being dried and treated with 3%
H2O2/H2O for 5 min to quench the endogenous human serum
peroxidases, this membrane was washed and blocked. After being
washed and dried, the membrane was cut into two equal pieces
and then processed by sequential reaction steps with either MAb
2C4.6 or MAb 3D1.4, peroxidase-labelled goat anti-mouse IgG (H&L)
and 4-chloro-1-naphthol/3,3’diaminobenzidine (CND) substrate. The
results were obtained from one of duplicate experiments performed
that gave similar results.prepared in human sera and then added at 10 μl/dot to
nitrocellulose membranes. The membranes were dried,
quenched for 5 min with 3% H2O2/H2O, blocked, washed
with PBS containing 0.02% NaN3, and then air dried. After
processing, MAb 2C4.6 was observed to bind equally to
the s/e NS1 glycoprotein of each DENV serotype, again
with a maximum detection sensitivity of < 32 ng/ml
(< 0.32 ng dot) against each DENV serotype.
We previously observed that s/e DENV NS1 glycoproteins
were stable when dried on nitrocellulose membranes in dot-
blot and Western blot assay formats at ambient tempera-
tures for month-long periods (Falconar, unpublished). The
dot-blot assays developed in the current study were also
assessed for their stability. The s/e NS1 glycoprotein of each
DENV serotype diluted in human sera were quenched for 5
min with 3% H2O2/H2O, blocked, washed with PBS
containing 0.02% NaN3, air dried, placed in sealed plastic
bags and stored for 1 month at ambient temperature (mean:
28°C), 4°C, -20°C or -80°C before processing. After process-
ing them, the detection sensitivity for the NS1 glycoprotein
of each DENV serotype remained at < 32 ng/ml for the
membranes stored at 28°C and 4°C (Figure 5). However, the
detection sensitivity for one or more DENV serotypes was
reduced for membranes stored at -20°C and -80°C.
Reduction of the total dot-blot assay time to 3 hours
To determine if the dot-blot assay could be performed
in 3 h, the same serial dilutions of the s/e NS1 glycopro-
tein of all four DENV serotypes were used, and the fol-
lowing steps were performed at ambient temperature
(28°C): i) loading and drying (40 min), ii) quenching
(5 min), iii) washing (0.3 min), iv) blocking (50 min), iv)
washing (0.3 min), v) primary MAb (MAb 2C4.6) reac-
tion (30 min), vi) washing (3 × 1 min), vii) labelled second-
ary antibody reaction (25 min), viii) washing (3 × 1 min),
ix) substrate reaction (10 min), and x) washing (1 min)
(total assay time: 178 min). In this study, there was no
observable reduction in the maximum DENV-1 to -4 s/e
NS1 glycoprotein detection sensitivities of < 32 ng/ml
(Figure 6) compared to those obtained using the longer
assay time (Figures 2, 3 and 4); therefore, these simple
dot-blot assays could be performed relatively rapidly.
Discussion
Reaction bias of the MAbs used to detect the DENV s/e
NS1 glycoprotein
We previously obtained five MAbs (1A12.3, 3D1.4, 3A5.4,
4H3.4 and 1C6.3), which were used to define DENV com-
plex epitopes on the NS1 glycoprotein [3], and another
MAb was generated as a sub-clone (1G5.4-A1-C3) [21].
These MAbs either did not react equally with the s/e NS1
glycoproteins of each DENV serotype in Western blot as-
says (e.g., MAbs 1C6.3 and 1G5.4-A1-C3) [5,21,22] or
with the corresponding LX1 epitope sequences of each
Figure 5 Detection sensitivities of MAb 2C4.6 against DENV s/e
NS1 glycoproteins stored at different temperatures. Serial two-
fold dilutions from 512 to 2 ng/ml of immunoaffinity-purified s/e
NS1 glycoprotein of each DENV serotype (DENV-1 to DENV-4) or
buffer only (0), prepared in undiluted human sera were added at 10
μl volumes to four paired 5-mm squares marked on a nitrocellulose
membrane. After being dried and treated with 3% H2O2/H2O for 5
min to quench the endogenous human serum peroxidases, this
membrane was washed and blocked. After being washed and dried,
the membrane was cut into four equal pieces, sealed in plastic bags
and stored either at ambient temperature (mean 28°C), 4°C, -20°C or
-80°C for 1 month. These membranes were then processed by
sequential reaction steps with MAb 2C4.6, peroxidase-labelled goat
anti-mouse IgG (H&L) and 4-chloro-1-naphthol/3,3’diaminobenzidine
(CND) substrate. The results were obtained from one of duplicate
experiments performed that gave similar results.
Figure 6 Detection sensitivities of MAb 2C4.6 against the DENV
s/e NS1 glycoproteins in a 3 h assay. The maximum detection
sensitivity of the assay was assessed against the same serial dilutions
of immunoaffinity-purified s/e NS1 glycoproteins when the total dot-
blot assay time was reduced to 3 h. For this assay, serial two-fold
dilutions from 512 to 2 ng/ml of immunoaffinity-purified s/e NS1
glycoprotein of each DENV serotype (DENV-1 to DENV-4) or buffer
only (0), prepared in undiluted human sera were added at 10 μl
volumes to paired 5-mm squares marked on a nitrocellulose
membrane. After being dried and treated with 3% H2O2/H2O for 5
min to quench the endogenous human serum peroxidases, this
membrane was washed and blocked before being processed by
sequential reaction steps with MAb 2C4.6, peroxidase-labelled goat
anti-mouse IgG (H&L) and 4-chloro-1-naphthol/3,3’diaminobenzidine
(CND) substrate. The results were obtained from one of duplicate
experiments performed that gave similar results.
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3D1.4, 3A5.4, 4H3.4 and 1A12.3) [4]. The present study
confirmed that MAb 3D1.4 did not react equally with the
s/e NS1 glycoprotein from the different DENV serotypes,
showing high sensitivity for the s/e NS1 glycoprotein of
DENV-1 (< 32 ng/ml), but lower sensitivity for those of
the other serotypes, particularly DENV-2 (< 128 ng/ml)
(Figure 4). It is therefore not surprising that thecommercially-available DENV s/e NS1 glycoprotein detec-
tion assays showed much higher sensitivities with DENV-
1 infected patients’ sera than with sera from patients
infected with the other DENV serotypes, particularly
DENV-2 and DENV-4 [9-11,14]. This suggests that these
assays all employ MAbs binding to the LX1 epitope. We
attempted to generate better MAbs by immunising BALB/
c mice with a mixture of s/e NS1 glycoproteins from each
DENV serotype, screening resultant hybridomas against
known concentrations of these glycoproteins using
ELISAs, preparative Western blot strips, and dot-blot
assays.
Sensitivity of the DENV s/e NS1 glycoprotein assays
Our simple dot-blot assays showed maximum sensitiv-
ities of < 32 ng/ml, more than adequate to detect con-
centrations of s/e NS1 glycoproteins from DENV-1 and
DENV-3 (from 43 to 15 219 ng/ml) that were detected
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the Platelia assay could only detect low concentrations
(2–163 ng/ml) of the s/e NS1 glycoprotein in sera from
patients infected with DENV-2. Indeed, the DENV-2 s/e
NS1 glycoprotein was undetectable in one-third of these
patients, despite levels of viremia similar to those
infected with DENV-1 and DENV-3 [15]. These observa-
tions indicate that the DENV-2 s/e NS1 glycoprotein
was poorly detected by the MAb used in this assay. This
was strongly supported by detection of DENV-2 s/e NS1
glycoprotein in 71% (10/14) and 89% (16/18) of patients
who subsequently developed DF and DHF, respectively,
and their high concentrations of the s/e NS1 glycopro-
tein (up to 14 000 ng/ml) and high virus titres
(viraemias) [23], similar to those in DENV-1 and DENV-
3 infected patients [15]. In contrast to the Platelia
assay, this non-commercially developed capture ELISA
incorporated a DENV-2 NS1 glycoprotein-specific
MAb, 1H7, along with rabbit anti-DENV-2 NS1 glyco-
protein PAbs [3,6,23]. Importantly, this non-commercial
assay detected the DENV-2 s/e NS1 glycoprotein at > 600
ng/ml in 21% (3/14) and 72% (13/18) of the patients
who subsequently developed DF and DHF, respectively,
thereby providing a sensitivity of 72% and a specificity
of 79% for identifying patients who subsequently devel-
oped SDD (DHF/DSS) [23]. However, unlike the DENV-2
NS1 glycoprotein specific MAb 1H7.4 and the MAbs used
in commercial DENV s/e NS1 glycoprotein detection
assays, MAb 2C4.6 reacted equally with the s/e NS1
glycoproteins of each DENV serotype in human serum
samples.
Effect of patient PAbs on DENV s/e NS1 glycoprotein
detection assays
Both the Platelia and Pan-E detection ELISAs showed
markedly reduced sensitivity when used to test sera from
patients with secondary DENV-2 infections compared
with sera from patients with primary DENV-2 infections
[24]. Furthermore, the presence of anti-DENV IgM and,
to a much greater extent, anti-DENV IgG PAbs, in sera
from Vietnamese patients reduced the sensitivity of the
Platelia assay [13]. Thus, the combination of MAbs that
do not react equally with the s/e NS1 glycoproteins of
each DENV serotype and the presence of patient PAbs
against the DENV NS1 glycoproteins (generated during
secondary DENV infections) is likely to be responsible
for the low sensitivity of these commercial assays. The
incorporation of simple acid treatment and neutralisa-
tion steps, which disrupt circulating immune complexes
(CICs) present in the patient sera, improved the detec-
tion of the DENV s/e NS1 glycoprotein (particularly in
patients infected with DENV-2) in dot-blot assays of
acute-phase primary and secondary sera from Indonesian
patients [17]. While these acid treatment and neutralisationsteps had little effect on the sensitivity to the DENV-1,
DENV-3 and DENV-4 s/e NS1 glycoproteins (although
only one DENV-4-infected patient was tested), they
markedly increased the detection of the DENV-2 s/e
NS1 glycoprotein in infected patient sera from 25% to
100% [17]. In contrast, only a modest increase in sensi-
tivity (9%) was reported when these acid treatment and
neutralisation steps were performed on patient sera
prior to testing in the Platelia assay; however, the DENV
serotypes in those patients had not been determined
[25]. The weak reaction between MAb 3D1.4 and the s/e
NS1 glycoprotein of DENV-4 in the dot-blot assays ob-
served in the current study (Figure 4) was consistent
with the lower detection rates observed when the
commercial assays were used to test acute-phase sera
from patients infected with DENV-4 [9-11,14]. Further
studies are needed to assess whether these acid treatment
and neutralisation steps are more suited to improving the
detection of the DENV-2 and DENV-4 s/e NS1 glycopro-
teins present in patient CICs in the dot-blot assays, as they
bind more rapidly to nitrocellulose membranes after
neutralisation than they do in the capture ELISAs
where such delays may result in the reformation of
CICs. Acid treatment of patient sera for the DENV s/e
NS1 glycoprotein detection dot-blot assays was however
performed for 60 minutes before neutralization [17],
thereby adding additional time to the assay. This would
have also dissociated the DENV NS1 glycoproteins into
their monomeric forms [7]. Alternative agents that disrupt
patient CICs more quickly are likely to be useful in these
assays (see below).
Combination of single-patient DENV-specific IgM/IgG and
DENV s/e NS1 glycoprotein detection results for DENV
diagnosis
The sensitivity of commercial assays is reportedly increased
by combining results from DENV NS1 glycoprotein assays
with those from anti-DENV-specific pre-membrane (prM)
and envelope (E) (prM/E) glycoprotein IgG and/or IgM
detection assays [10-12,26]. However, false-positives have
been reported using some DENV NS1 glycoprotein or
anti-DENV prM/E glycoprotein IgG or IgM antibody
detection assays during secondary DENV infections or
with sera from patients carrying other infectious agents or
from healthy donors [10-12]. These false-positives may
account for the reported increased sensitivity of such
combined assays, in addition to the use of sera from
patients predominantly infected with DENV (DENV-1 or
DENV-3) serotypes, more easily detected by these com-
mercial assays: a) DENV-1 (DENV-1: 56.3%; DENV-2:
37.6%; DENV-3: 6.6%; DENV-4: 0.0%) [26]; b) DENV-1
plus undetermined DENV serotypes (DENV-1: 39.3%;
DENV-2: 16.3%; DENV-3: 6.3%; DENV-4: 8.4%; undeter-
mined DENV serotypes: 29.7%) [11]; or c) DENV-3 plus
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16.2%; DENV-3: 47.5%; DENV-4: 2.0%; undetermined:
33.3%) [12]. Importantly, some DENV patients (termed
*LS patients) generated low levels of anti-DENV prM/E
glycoprotein reactive IgG antibodies, even during second-
ary DENV infections [19]. Indeed, 40% of patient sera may
be negative for IgG and IgM antibodies against the DENV
E and prM glycoproteins on day 3 after the onset of fever
[19], and DENV prM/E glycoprotein-specific IgM anti-
bodies were not generated during secondary DENV infec-
tions in patients from either Asia (28% IgM-negative) [27]
or the Americas (33% IgM-negative) [19]. These problems
were further confirmed by the very low sensitivity ob-
served for a commercially-available combined DENV
diagnostic assay used to test a panel of sera from patients
with fully characterised DENV infections, primarily sec-
ondary DENV-2 or DENV-4 infections [Falconar and
Romero-Vivas, unpublished]. DENV-2 and DENV-4 are
the dominant DENV serotypes in our DHF/DSS-endemic
study site in the Americas (Colombia) [19,20]. These sero-
types were maintained in the Americas after their intro-
duction [28,29] and are important causes of DENV
epidemics (e.g. in Mexico [30], Nicaragua [31], Guatemala
and Honduras [32], Brazil [33]) and the Caribbean islands
(e.g., Martinique [34]), as well as in Asia (e.g., Thailand
[35], Singapore [36] and China [37]). Thus, there is an ur-
gent need to develop simple, inexpensive, sensitive and ro-
bust NS1 glycoprotein detection assays that can equally
detect the s/e NS1 glycoprotein of each DENV serotype.
Advantages of DENV s/e NS1 glycoprotein detection dot-
blot assays using improved MAbs
The failure to maintain DENV patient sera at low tem-
peratures before testing resulted in an inability to detect
the glycoprotein in acute-phase sera from patients with
primary DENV-2 infections [6]. Thus, the ability to
store antigenically stable prepared membranes at 28°C
(Figure 5), is highly desirable. These membranes can
then be immediately processed using basic equipment
and reagents, and by staff with minimal training. Alter-
natively, they can be transferred to other laboratories at
ambient temperatures for processing. As a result, large
numbers of samples from patients with febrile illnesses
can be screened easily, inexpensively (approximately US
$ 0.05/sample, i.e., 100–200 times less expensive than
commercial detection assays) and relatively rapidly for
DENV infections in all endemic areas. Importantly, sim-
ple definitive clinical criteria (conjunctival injection, ab-
dominal pain and venipuncture bleeding) can also be
applied to patients by staff from such clinics with min-
imal training, to identify the relatively low numbers of
DENV-infected patients who will subsequently develop
SDD (DHF/DSS), so that prompt hospital-based therapy
can be provided [19].Conclusions
This is the first study to assess quantitatively the sensi-
tivity of a DENV NS1 glycoprotein detection assay using
known concentrations of s/e NS1 glycoprotein from
each DENV serotype. The main findings were that: i) hy-
bridomas were generated and successfully screened for
MAbs that showed an equally strong reaction with puri-
fied s/e NS1 glycoprotein of each DENV serotype; ii) op-
timal quenching of endogenous peroxidases in human
sera was achieved using 3% H2O2 (in H2O) for 5 min;
iii) the maximum sensitivity of MAb 2C4.6 for the s/e
NS1 glycoprotein of each DENV serotype was < 32 ng/
ml (< 0.32 ng/dot); iv) the addition of 1 mM Ni2+ to the
substrate mixture reduced the sensitivity of the dot-blot
assays; v) s/e NS1 glycoproteins of each DENV serotype
in human sera were stable when dried on nitrocellulose
membranes at ambient temperature (28°C) or when
stored at 4°C for at least 1 month before processing; vi)
the total assay time was reduced to 3 h without any loss
of sensitivity; vii) the estimated cost of these assays was
US$ 0.05/sample, and vii) the sensitivity of MAb 2C4.6
for the s/e NS1 glycoprotein of the DENV-2, DENV-3
and DENV-4 serotypes was superior to that of MAb
3D1.4 in these assays.
Dot-blot assays, such as the one developed here, have
the potential for use as simple, robust, inexpensive and
relatively rapid diagnostic tools in DENV-endemic coun-
tries, where there are an estimated 50-100 million infec-
tions annually [1].Further studies
We are presently testing whether improved alternative
methods for disruption of patient CICs together with al-
ternative detection methods can be used to increase the
sensitivities of these dot-blot assays by 10 to 100-fold
and to reduce the total assay time to the same (or less)
than that required to perform the Pan-E, Platelia and
Standard Diagnostic DENV NS1 glycoprotein detection
ELISAs (2.5 hours).
We also wish to fully evaluate these dot-blot assays
using large numbers of patient sera collected during the
acute phase of primary and secondary DENV infections
caused by each DENV serotype (i.e. n > 200) which have
been typed by full IgM/IgG ELISA titrations and DENV
isolation followed by serotype determinations, together
with full clinical details [19,20]. Since some commercial
DENV s/e NS1 detection assays have also been shown to
give false positives using normal human sera, and sera
from patients with some other viral or bacterial diseases
[11], we will also determine whether MAb 2C4.6 will
not generate such false positive reactions in these assays.
If these studies are successful, MAb 2C4.6 may be suit-
able for use in a rapid (5-10 min) point-of-care format.
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Ethics statement
The collection of 5 ml blood samples from two clinically
healthy human volunteers to obtain the normal human
sera used in this study was approved by the University
del Norte Ethics Committee. All animal experiments
were approved by the Universidad del Norte Ethics
Committee following the guidelines for the care and use
of experiment animals established by the Colombian
government, and following NIH guidelines.
Study site
Barranquilla is the principal seaport of Colombia and lies
at the mouth of the Magdalena River on the Caribbean
coast. All four DENV serotypes have become endemic in
the city, with severe dengue disease (SDD: DHF/DSS)
being confirmed since 1997. The isolation of all four
DENV serotypes of DENV (DENV-1 (S#14 strain),
DENV-2 (S#42 strain), DENV-3 (S#25 strain) and
DENV-4 (S#10 strain) in insect (C6/36) cells was
performed as described previously [19,20].
Purification of MAbs and preparation of immunoaffinity
columns
The purification of mouse MAbs of the IgG1, IgG2a and
IgG2b subclasses and the preparation of immunoaffinity
columns were carried out as described previously
[3,21,22]. MAb 3A5.4 was used for these studies due to
its ability to react with the s/e NS1 glycoproteins of each
DENV serotype, as well as the s/e NS1 glycoprotein of
YFV. Briefly, highly concentrated stocks of MAb 3A5.4
were diluted in phosphate buffered saline (PBS) (pH 7.6)
and slowly passed through a protein G-Sepharose
(P3296, Sigma-Aldrich, USA) column, washed with PBS,
eluted using 0.1 M glycine/HCl (pH 2.5), and 0.9-ml
fractions were immediately neutralised with 100 μl of
2 M Tris/HCl (pH 7.8). High-MAb-containing fractions
were identified using the bicinchoninic acid (BCA) pro-
tein assay (BCA-1, Sigma-Aldrich, USA), pooled and re-
peatedly dialysed against 2 litre volumes of 0.2 M
NaHCO3/0.5 M NaCl (pH 8.9). Cyanogen-bromide-
activated Sepharose 4B (0.8 g) (C9142, Sigma-Aldrich,
USA) was pre-swollen and then washed with 500 ml of
ice-cold HCl (1 mM). MAb 3A5.4 (12–15 mg) in 5 ml of
the dialysate was then added, and the capped columns
were incubated by inversion overnight at 4°C. The excess
sites were then blocked with 1M ethanolamine/PBS/HCl
(pH 9.0) for 2 h at ambient temperature. These columns
were then subjected to nine cycles of high and low pH
oscillations using 0.1 M glycine/HCl containing 1 M
NaCl (pH 3.5) and 50 mM Tris/HCl containing 1 M
NaCl (pH 9.0), before being washed with 10 mM
diethylamine/PBS (pH 11.2) and then PBS containing
0.2% (wt/vol) NaN3 before being stored at 4°C.Growth of DENV strains of each DENV serotype and YFV
and the immunoaffinity purification of their s/e NS1
glycoproteins
DENV strains of all four DENV serotypes were propa-
gated in both insect (C6/36) cell and mammalian (Vero)
cell monolayers as described previously [5,19]. For these
studies, YFV (17D-204 vaccine strain) was also propa-
gated in both C6/36 and Vero cells. High-titre seed
stocks of each virus were prepared in 80 cm2 cultures of
70% confluent C6/36 cells maintained in Leibovitz L-15
medium (L4386, Sigma-Aldrich, USA) containing 10%
(vol/vol) tryptose phosphate broth (T9157, Sigma-
Aldrich, USA) with 10% (vol/vol) foetal calf serum
(FCS), pyruvate, L-glutamine and antibiotics (referred to
hereafter as insect cell growth medium (ICGM)). Cell
culture supernatants were collected on days 4 and 8
after infection, clarified by centrifugation and stored at -
80°C. These stocks were used to infect 70%-confluent
mammalian (Vero) cell monolayers maintained in
medium 199 containing Na2HCO3, 3.5% FCS, pyruvate,
L-glutamine and antibiotics (referred to hereafter as
mammalian cell growth medium (MCGM) in 10 large
(225 cm2) flasks. After growth at 37°C in a 5% (vol/vol)
CO2 atmosphere for 4 days, the supernatants were col-
lected and replaced by fresh MCGM and incubated for a
further 4 days before being harvested. These superna-
tants were made up to 20 mM Tris/HCl (pH 7.4), 1 mM
PMSF, 5 mM Na2EDTA, 0.05% (wt/vol) NaN3, 7% (wt/
vol) polyethylene glycol 8000 (89510, Sigma-Aldrich,
USA) and 0.4 M NaCl using stock solutions. The DENV
particles (virions) were then allowed to aggregate over-
night at 4°C before being removed by centrifugation at
8,000 × g for 30 min at 4°C. The clarified supernatants
were then slowly (1 ml/min) passed through the MAb
3A5.4 or 3D1.4 immunoaffinity columns. After washing
with loading buffer, the bound extracellular/secreted
(s/e) NS1 glycoproteins were eluted in their native
homo-hexameric form using 20 mM diethylamine in
10 mM Tris/HCl containing 150 mM NaCl, PMSF and
EDTA and 0.4 ml fractions were immediately neutralised
with 100 μl of 1M Tris/HCl (pH 7.2). Protein concentra-
tions were determined in ELISA plates using 10 μl of sam-
ple in 200 μl of BCA reagent (BCA-1, Sigma-Aldrich, USA)
with standard concentrations (16 mg/ml to 125 μg/ml serial
dilutions) of bovine serum albumin (A7906: Sigma,
USA) concentrations prepared in neutralised elution
buffer. ELISA plates were incubated at 37°C for 60 min
and then absorbance was determined at 570 nm (MRX,
Dynax, USA), and protein concentrations were derived
from the standard curves. Fractions containing the
DENV s/e NS1 glycoproteins were concentrated by cen-
trifugation dialysis at 1,000–2,000 × g (Centricon 10,
Amersham, UK) against RPMI-1640 medium (R6504,
Sigma, USA) containing a cocktail of protease inhibitors
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were then determined again and fractions were stored
at -80°C.
One 25 cm2 flask of DENV-2 infected Vero cells was
also used to prepare an infected cell lysate for the Western
blot assays by discarding the supernatant and repeat-
edly washing the cells with RPMI medium before the
addition of 2 ml of 32 mM orthophosphoric acid/58
mM Tris base (pH 6.7) (345245/T6066: Sigma-Aldrich,
USA) containing 10% sodium dodecyl sulphate (SDS)
(L3771, Sigma, USA) (cell-lysis buffer). After repeated
passage through a 23-gauge needle to break the DNA,
the cell lysate was centrifuged at 200 × g and aliquots of
the supernatant were stored at -80°C.
Immunisation of mice and production of mouse MAbs
The immunisation and use of halothane in oxygen to an-
aesthetise BALB/c mice, and the production and cloning
of MAbs were carried out as described previously
[5,22,38]. Briefly, a group of three 6-week-old female
BALB/c mice (Universidad Nacional, Bogota, Colombia)
were immunised by the combined subcutaneous (s.c.; 0.1
ml) and intra-peritoneal (i.p.; 0.4 ml) routes with a mix-
ture of 5 μg of the purified e/s NS1 glycoprotein of each
DENV serotype (i.e., 20 μg/mouse) emulsified in
complete Freund’s adjuvant (F5881, Sigma, USA). These
mice were also each injected with 0.5 μg of mouse
interleukin-12 (IL-12) by the i.p. route on days 1, 3, 5
and 7 after the immunisations to increase the produc-
tion of PAbs of the IgG2a subclass [39]. Three weeks
later, the mice were boosted with the sample antigen
emulsified in incomplete Freund’s adjuvant (F5506:
Sigma, USA) at the same dose and via the same route,
and they also received the same multiple IL-12 injec-
tions. Four weeks later, the mice were anaesthetised and
blood samples were obtained from the retro-orbital
sinus. The highest responding mouse, as determined by
the indirect ELISA titres against the s/e NS1 glycopro-
tein of each DENV serotype, was then immunised with
10 μg each of the DENV-1 (S#14 strain), DENV-2 (S#42
strain), DENV-3 (S#25 strain) and DENV-4 (S#10 strain)
s/e NS1 glycoproteins (40 μg in total) in RPMI medium
by the combined intravenous (i.v.) route in the tail vein
(100 μl) and the i.p. route (300 μl). Three days later, this
mouse was anesthetised and humanely killed by cervical
dislocation, immersed in 70% ethanol and transferred to
a class II laminar flow cabinet. The spleen cells were
aseptically removed in RPMI medium containing 10%
MAb-cloning tested quality FCS (FCS Premium:
Biomeda, USA) and then centrifuged at 200 × g for 10
min at 28°C. SP2/0 Ag14 plasmacytoma cells (ATCC,
USA), grown in RPMI medium containing 20% FCS and
pyruvate, L-glutamine and antibiotics (PGAB), were
harvested. The spleen and plasmacytoma cells werecounted and mixed at a 10:1 ratio, co-centrifuged at
250 × g and the supernatant was discarded. One milli-
litre of 45% (wt/vol) polyethylene glycol 4000 (Merck
BDH, UK) containing 5% dimethylsulfoxide (D2650,
Sigma, USA)/PBS (pH 8.1) was slowly added to the loos-
ened cell pellet over a period of 1 min with constant agita-
tion before being slowly diluted with 20 ml of Hank’s
balanced salt solution (H9394, Sigma, USA). After incuba-
tion at 28°C for 30 min, the cells were pelleted by centrifu-
gation at 200 × g, the supernatant was discarded, and the
cells re-suspended in 200 ml of RPMI medium containing
20% FBS, 1 × HAT (H0262: Sigma, USA) and PGAB be-
fore being added to 96-well culture plates (NUNC, USA)
at 200 μl/well. After incubation at 37°C in 5% CO2/air for
5 days, 100 μl of the medium was changed and thereafter
150 μl was changed every 3 days until the DENV s/e NS1
glycoprotein MAb-positive wells were expanded. The 150
μl volumes collected from each well were tested by ELISA
for reactions against the purified DENV s/e NS1 glycopro-
tein of each DENV serotype, and the contents of the wells
containing MAbs that cross-reacted with the s/e NS1
glycoprotein of multiple DENV serotypes were transferred
into 48-well plates (Costar, USA). HAT selection medium
was subsequently substituted with medium containing HT
(H0137, Sigma, USA) after 14 days, from which these hy-
bridomas were never weaned. The culture supernatants
were then tested for reactivity with the s/e NS1 glycopro-
tein from each DENV serotype in dot-blot assays. Western
blot assays were also performed to test reactivity against a)
the NS1 glycoproteins from each DENV serotype and
YFV, b) the 2–mercaptoethanol reduced DENV-2 s/e NS1
glycoprotein, the cell-associated DENV-2 NS1 glycopro-
tein present in a crude SDS-lysate of DENV-2 infected
Vero cells, and c) the DENV-2 s/e NS1 glycoprotein
present in a human serum sample after the sera had been
treated with 3% H2O2/PBS for 30 min to quench endogen-
ous peroxidases. Thus, these assays were used to select
wells containing hybridomas that secreted MAbs that spe-
cifically reacted with the s/e NS1 glycoprotein of each
DENV serotype, and which would not cross-react with
proteins in Vero cells or human sera.
Hybridomas that secreted the desired MAbs were
cloned twice by limiting dilution in 96-well cell culture
plates containing 2–4 × 104/well CD1 (Swiss out-bred)
mouse peritoneal macrophage feeder layers. Single wells
were identified using an inverted microscopy, the super-
natants were screened by ELISA against DENV s/e NS1
glycoproteins and the resultant cloned hybridomas were
further sequentially expanded and harvested, pelleted by
centrifugation and the cells slowly (-1°C/min) frozen to -
80°C after being re-suspended in ice-cold 10% (vol/vol)
DMSO/FCS, before being transferred to liquid nitrogen.
From this fusion, MAb 2C4.6 and a number of other
cloned hybridomas were selected.
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kit using goat PAbs specific for each mouse IgG subclass
in radial immunoassays (ISO-2, Sigma, USA), according
the manufacturer’s instructions.
Immunoassays
The indirect DENV s/e NS1 glycoprotein ELISA was
performed as described previously [5,21,23]. Briefly, the
immunoaffinity-purified DENV-2 s/e NS1 glycoproteins
(see above) or the negative-control antigen, bovine
serum albumin, were diluted to 3 μg/ml in carbonate/bi-
carbonate buffer (pH 9.8), loaded into 96-well ELISA
plates (Immulon 2, Dynatech, USA) and adsorbed over-
night at 4°C. After washing with PBS containing 0.05%
(vol/vol) Tween20 (PBS/T), blocking with 1% (wt/vol)
gelatin/PBS for 2 h at 25°C and washing again with PBS/
T, 50 μl volumes of the undiluted hybridoma wells were
transferred to each ELISA well and allowed to react at
37°C for 60 min. After washing with PBS/T, the bound
MAbs were detected with sequential reaction steps
using peroxidase-labelled goat anti-mouse IgG heavy
and light (H&L) chain reactive (115-035-166, Jackson
ImmunoResearch, USA) in PBS/T/G, washing with PBS/T,
incubation with o-phenylenediamine (opd) in citrate/phos-
phate buffer (pH 5.0) containing H2O2 and the absorbance
values measured at 490 nm (MRX: Dynex, USA).
The Western blot assays were performed as described
previously [3,21,22]. Samples were prepared using 1.0 μg
s/e NS1 glycoprotein of each DENV serotype added to
160 μl of stacking buffer containing 0.5% (wt/vol) SDS,
32 μl of 0.25% (wt/vol) bromophenol blue in 50% gly-
cerol/H2O, with (all DENV serotypes) or without
(DENV-2 s/e NS1 glycoprotein) 1% (vol/vol) 2-
mercaptoethanol (M3148: Sigma, USA). In addition, 160
μl of a DENV-2 infected Vero cell lysate (see cell cul-
ture) and 30 μl of a normal human serum sample (which
had been diluted 1 in 4 with PBS) were both treated with
3% (vol/vol) H2O2 (H1009, Sigma, USA) for 60 min at
28°C to quench endogenous human serum peroxidases,
before the addition of the 5 × stacking buffer and 1.0 μg
of DENV-2 s/e NS1 glycoprotein (total volume 160 μl).
Both were then treated with 32 μl of 0.05% (wt/vol)
bromophenol blue in 50% glycerol/H20. These samples
were then heated at 100°C for 3 min. After cooling and
centrifugation, they were then loaded onto 8–9% (wt/
vol) preparative SDS/PAGE gels (Miniprotean II: Bio-
Rad, UK) and subjected to electrophoresis (15–20
constant mA/gel) and subsequent electro-blotting at 160
mA/gel (Sartoblot II, Sartorius, UK) onto 0.2-μm pore-
sized nitrocellulose membranes (BioTraceNT, PAL
LifeSciences, USA) before being dried. These membranes
were then blocked using 3% (wt/vol) skimmed milk pow-
der (Marvel, Cadbury, UK)/PBS (PBS/T/M) containing
0.02% (wt/vol) NaN3, washed with PBS/T, dried and thencut into 3-mm wide strips. Preparative blot strips of the re-
duced (DENV-2 s/e NS1 glycoprotein only) and non-
reduced (s/e NS1 glycoproteins of all DENV serotypes and
YFV, DENV-2 infected Vero cells and human sera which
contained the DENV-2 s/e NS1 glycoprotein) were taped
together with waterproof autoclave tape and allowed to
react with 0.5 ml of the MAb supernatants of two 500 μl
samples (1 ml total) from 48-well cultures diluted with an
equal volume of PBS/T containing 2% (wt/vol) skimmed
milk powder for 2 h at ambient temperature. After washing
with PBS/T, the bound MAbs were detected using sequen-
tial reaction steps with peroxidase-labelled goat anti-mouse
IgG (H&L) (115-035-166: Jackson ImmunoResearch,
USA) in PBS/T/G, washing with PBS/T, PBS and then
reacting the membranes with 4-chloro-1-naphthol/
3,3’diaminobenzidine (C8890/D8001, Sigma, USA) (CND)
substrate in PBS containing 0.006% (vol/vol) H2O2.
For the dot-blot assays, 0.5-cm squares were marked on
the nitrocellulose membranes using an 8B graphite pencil
(Staedtler, Germany). Duplicate, serial, two-fold or three-
fold dilutions of the immunoaffinity-purified s/e NS1 gly-
coproteins prepared in normal human sera collected from
anti-DENV IgM and IgG-negative patients [19] were
added at 10 μl/dot and were air dried. Different methods
were assessed to quench the endogenous peroxidases in
the human sera present on these dot-blots. For this study,
solutions of 3% H2O2 diluted from a 30% (vol/vol) stock
solution (H1009, Sigma Aldrich, USA) in 40% (vol/vol)
MeOH/PBS, PBS or H2O were tested. These dot-blot as-
says were then processed as described for the Western
blot assays to identify the detection sensitivities of
MAb 2C4.6 against the s/e NS1 glycoprotein of each
DENV serotype when reacted at a concentration of 5–
10 μg/ml with serial dilutions of each of them. The
sensitivities of MAb 2C4.6 and 3D1.4 against known
concentrations of the s/e NS1 glycoprotein of each
DENV serotype were then compared. The reactions of
other MAbs anti-NS1 MAbs (1G5.4-A1-C3 and 1B6.3) of
the IgG2b subclass, which defined a DENV-2 > DENV-
4 > DENV-1 > DENV-3 and DENV-2-specific responses
against the s/e NS1 glycoprotein of each DENV serotype
in Western blot assays respectively [3,21,22], were also
tested for their reactions in these dot-blot assays.
In addition, we assessed whether: a) 1 mM Ni2+ (NiCl2)
could increase the sensitivities of these assays when added
to the 4-chloro-1-naphthol/3,3’ diaminobenzidine (CND)
substrate mixture; b) the assays could be successfully
processed without loss of detection sensitivities after sam-
ple addition and blocking, washing with PBS containing
0.01% NaN3 and storing after drying for 1 month at 28°C
(ambient temperature), 4°C, -20°C and -80°C; and c) the
total assay time could be reduced to 3 h without significant
loss of detection sensitivity when they were performed at
ambient temperature.
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